Table 3.

Maximum sNfL Increase in Participants by Maximum Number of Gd+ Lesions

Maximum sNfL change for each group			Maximum No. of Gd+ lesions
Gd+ lesions	0	>0	1	2–3	4–9	≥10
	n = 101	n = 65	n = 12	n = 18	n = 21	n = 14
Mean sNfL ±SD	3.2 ± 6.6	12.1 ± 28.7	3.9 ± 8.4	5.6 ± 7.8	5.6 ± 7.8	36.0 ± 56.5
p-valuea	─	0.003	0.89	0.58	0.32	<0.001
Median sNfL [IQR]	2.1 [0.5, 4.1]	4.10 [1.6, 12.2]	1.4 [0.4, 4.9]	3.0 [0.9, 8.6]	4.3 [2.7, 7.2]	19.5 [8.3, 35.8]
p-valueb	─	<0.001	0.94	0.31	0.003	<0.001
Participants with a peak sNfL ≥95th percentile of 19.6 pg/mL, n (%)	11 (10.9)	19 (29.2)	2 (16.7)	4 (22.2)	3 (14.3)	10 (71.4)
Participants with no sNfL peak > baseline, n (%)	18 (17.8)	7 (10.7)	3 (25.0)	3 (16.7)	1 (5.0)	0 (0.0)

Maximum % sNfL change for each group			Maximum No. of Gd+ lesions
Gd+ lesions	0	>0	1	2–3	4–9	≥10
	n = 101	n = 65	n = 15	n = 25	n = 16	n = 9
Mean ± SD	38.2 ± 54.6	145.1 ± 223.1	48.4 ± 100.5	92.2 ± 130.3	103.8 ± 127.7	371.1 ± 355.2
p-valuea	─	<0.001	0.79	0.10	0.04	<0.001
Median [IQR]	22.8 [5.8, 66.9]	63.9 [18.2, 190.0]	20.0 [5.3, 64.6]	36.7 [7.6, 127.7]	68.2 [31.2, 100.7]	239.6 [117.5, 423.6]
p-valueb	─	<0.001	0.73	0.28	0.003	<0.001
Participants with % change in sNfL ≥95th percentile of +68.8%, n (%)	25 (24.8)	29 (44.6)	2 (16.7)	6 (33.3)	10 (47.6)	11 (78.6)

Abbreviations: Gd+ = gadolinium-enhancing; IQR = interquartile range; sNfL = serum neurofilament light chain.

^at-test p-value; p-value indicates comparison with Gd+ = 0 group.

^bWilcoxon rank sum test, p-value indicates comparison with Gd+ = 0 group.